Healthcare provider profile · identity verified

Milton A Jimenez, MD

Allopathic & Osteopathic Physicians|Internal Medicine · MIAMI, FL · NPI 1437148384

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Milton A Jimenez, MD received $497.31 in general payments during 2025 across 5 reported records.

Impulse Dynamics (USA) Inc. accounted for 69.3% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 2 associated products.

Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Jardiance by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$497.31

5 reported records · 2 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Impulse Dynamics (USA) Inc.	Unresolved — no canonical attribution shown	$344.85	69.3%	3	2025
Boehringer Ingelheim Pharmaceuticals, Inc.	Unresolved — no canonical attribution shown	$152.46	30.7%	2	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$497.31	5

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
Optimizer Normalized: optimizer	Device	Impulse Dynamics (USA) Inc.	$344.85	3	2025
Source payment records 2025-02-03 · Impulse Dynamics (USA) Inc. · $84.08 · Open Payments source 2025-05-29 · Impulse Dynamics (USA) Inc. · $127.76 · Open Payments source 2025-11-25 · Impulse Dynamics (USA) Inc. · $133.01 · Open Payments source
OFEV Normalized: ofev	Drug	Boehringer Ingelheim Pharmaceuticals, Inc.	$152.46	2	2025
Source payment records 2025-04-10 · Boehringer Ingelheim Pharmaceuticals, Inc. · $30.36 · Open Payments source 2025-12-09 · Boehringer Ingelheim Pharmaceuticals, Inc. · $122.10 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583	Jardiance · 2024 Exact normalized brand match · 1 Part D row	165	11

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	668	112
Eliquis	Apixaban	524	59
Losartan Potassium	Losartan Potassium	467	84
Amlodipine Besylate	Amlodipine Besylate	432	64
Gabapentin	Gabapentin	428	58
Levothyroxine Sodium	Levothyroxine Sodium	417	61
Famotidine	Famotidine	348	60
Metoprolol Tartrate	Metoprolol Tartrate	287	49
Donepezil Hcl	Donepezil Hcl	286	38
Memantine Hcl	Memantine Hcl	273	38
Omeprazole	Omeprazole	270	61
Tamsulosin Hcl	Tamsulosin Hcl	253	41
Metoprolol Succinate	Metoprolol Succinate	243	40
Clopidogrel	Clopidogrel Bisulfate	240	33
Metformin Hcl	Metformin Hcl	240	45
Lisinopril	Lisinopril	238	42
Furosemide	Furosemide	237	51
Sertraline Hcl	Sertraline Hcl	214	29
Escitalopram Oxalate	Escitalopram Oxalate	208	35
Pantoprazole Sodium	Pantoprazole Sodium	195	35
Montelukast Sodium	Montelukast Sodium	188	28
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	186	16
Simvastatin	Simvastatin	185	32
Mirtazapine	Mirtazapine	178	34
Jardiance	Empagliflozin	165	11
Bumetanide	Bumetanide	160	21
Entresto	Sacubitril/Valsartan	145	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	144	20
Carvedilol	Carvedilol	143	24
Rosuvastatin Calcium	Rosuvastatin Calcium	138	28
Novolog Flexpen	Insulin Aspart	124	16
Azelastine Hcl	Azelastine Hcl	116	54
Mupirocin	Mupirocin	111	56
Potassium Chloride	Potassium Chloride	110	23
Carbidopa-Levodopa	Carbidopa/Levodopa	109	15
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	107	32
Hydralazine Hcl	Hydralazine Hcl	101	14
Latanoprost	Latanoprost	100	21
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	99	50
Finasteride	Finasteride	96	15
Warfarin Sodium	Warfarin Sodium	94	suppressed
Ketoconazole	Ketoconazole	93	21
Nystop	Nystatin	92	47
Nifedipine Er	Nifedipine	88	15
Procrit	Epoetin Alfa	87	suppressed
Glipizide	Glipizide	84	15
Hydrochlorothiazide	Hydrochlorothiazide	84	19
Meloxicam	Meloxicam	84	23
Nystatin	Nystatin	81	39
Budesonide	Budesonide	75	11
Trazodone Hcl	Trazodone Hcl	75	15
Ipratropium Bromide	Ipratropium Bromide	73	13
Doxycycline Hyclate	Doxycycline Hyclate	72	37
Spironolactone	Spironolactone	71	14
Duloxetine Hcl	Duloxetine Hcl	70	suppressed
Fluticasone Propionate	Fluticasone Propionate	70	19
Quetiapine Fumarate	Quetiapine Fumarate	70	16
Allopurinol	Allopurinol	69	14
Levetiracetam	Levetiracetam	69	suppressed
Citalopram Hbr	Citalopram Hydrobromide	66	14
Humalog Kwikpen U-100	Insulin Lispro	64	11
Fiasp Flextouch	Insulin Aspart (Niacinamide)	62	11
Xarelto	Rivaroxaban	61	suppressed
Amiodarone Hcl	Amiodarone Hcl	60	11
Ondansetron Odt	Ondansetron	59	20
Atenolol	Atenolol	58	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	58	16
Alendronate Sodium	Alendronate Sodium	54	13
Irbesartan	Irbesartan	54	suppressed
Prednisone	Prednisone	54	19
Triamcinolone Acetonide	Triamcinolone Acetonide	54	20
Enulose	Lactulose	51	12
Tizanidine Hcl	Tizanidine Hcl	51	suppressed
Buspirone Hcl	Buspirone Hcl	50	suppressed
Memantine Hcl Er	Memantine Hcl	50	suppressed
Sucralfate	Sucralfate	49	suppressed
Levofloxacin	Levofloxacin	48	26
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	45	28
Baclofen	Baclofen	44	suppressed
Ezetimibe	Ezetimibe	43	suppressed
Januvia	Sitagliptin Phosphate	41	suppressed
Methenamine Hippurate	Methenamine Hippurate	40	suppressed
Primidone	Primidone	40	suppressed
Diltiazem Hcl	Diltiazem Hcl	39	suppressed
Tradjenta	Linagliptin	39	suppressed
Valproic Acid	Valproic Acid (As Sodium Salt)	39	suppressed
Pravastatin Sodium	Pravastatin Sodium	38	suppressed
Namzaric	Memantine Hcl/Donepezil Hcl	36	suppressed
Naproxen	Naproxen	36	19
Nystatin-Triamcinolone	Nystatin/Triamcinolone Acet	35	11
Santyl	Collagenase Clostridium Hist.	35	12
Azithromycin	Azithromycin	34	18
Timolol Maleate	Timolol Maleate	34	suppressed
Diclofenac Sodium	Diclofenac Sodium	33	suppressed
Dorzolamide-Timolol	Dorzolamide Hcl/Timolol Maleat	33	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	33	suppressed
Ozempic	Semaglutide	33	suppressed
Ranolazine Er	Ranolazine	33	suppressed
Amantadine	Amantadine Hcl	32	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	32	24
Albuterol Sulfate	Albuterol Sulfate	31	13
Levemir Flexpen	Insulin Detemir	30	suppressed
Midodrine Hcl	Midodrine Hcl	30	suppressed
Ssd	Silver Sulfadiazine	29	13
Doxazosin Mesylate	Doxazosin Mesylate	28	suppressed
Trulicity	Dulaglutide	28	suppressed
Alogliptin	Alogliptin Benzoate	27	suppressed
Divalproex Sodium	Divalproex Sodium	27	suppressed
Gentamicin Sulfate	Gentamicin Sulfate	27	15
Insulin Aspart Flexpen	Insulin Aspart	27	suppressed
Trintellix	Vortioxetine Hydrobromide	27	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	26	suppressed
Farxiga	Dapagliflozin Propanediol	26	suppressed
Levalbuterol Hcl	Levalbuterol Hcl	26	suppressed
Myrbetriq	Mirabegron	26	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	26	suppressed
Mounjaro	Tirzepatide	25	suppressed
Incruse Ellipta	Umeclidinium Bromide	24	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	24	suppressed
Bupropion Xl	Bupropion Hcl	23	suppressed
Celecoxib	Celecoxib	23	suppressed
Creon	Lipase/Protease/Amylase	23	suppressed
Olanzapine	Olanzapine	23	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	23	suppressed
Mometasone Furoate	Mometasone Furoate	22	suppressed
Vascepa	Icosapent Ethyl	22	suppressed
Digoxin	Digoxin	20	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	20	suppressed
Linzess	Linaclotide	20	suppressed
Carbamazepine	Carbamazepine	19	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	19	suppressed
Isosorbide Dinitrate	Isosorbide Dinitrate	19	suppressed
Pentoxifylline	Pentoxifylline	19	suppressed
Rivastigmine	Rivastigmine Tartrate	19	suppressed
Symbicort	Budesonide/Formoterol Fumarate	19	suppressed
Brilinta	Ticagrelor	18	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	18	14
Oxybutynin Chloride	Oxybutynin Chloride	18	suppressed
Pregabalin	Pregabalin	18	suppressed
Methylprednisolone	Methylprednisolone	17	13
Oseltamivir Phosphate	Oseltamivir Phosphate	17	14
Piperacillin-Tazobactam	Piperacillin Sodium/Tazobactam	17	suppressed
Advair Diskus	Fluticasone Propion/Salmeterol	16	suppressed
Ammonium Lactate	Ammonium Lactate	16	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	16	suppressed
Cefdinir	Cefdinir	16	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	16	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	16	suppressed
Haloperidol	Haloperidol	16	suppressed
Invokana	Canagliflozin	16	suppressed
Retacrit	Epoetin Alfa-Epbx	16	suppressed
Sildenafil Citrate	Sildenafil Citrate	16	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	15	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	15	suppressed
Cholestyramine	Cholestyramine (With Sugar)	15	suppressed
Enoxaparin Sodium	Enoxaparin Sodium	15	suppressed
Ertapenem	Ertapenem Sodium	15	suppressed
Glipizide Er	Glipizide	15	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	15	suppressed
Paroxetine Hcl	Paroxetine Hcl	15	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	14	suppressed
Amoxicillin	Amoxicillin	14	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	14	suppressed
Chlorthalidone	Chlorthalidone	14	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	14	11
Gemtesa	Vibegron	14	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	14	suppressed
Sodium Chloride	0.9 % Sodium Chloride	14	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	14	suppressed
Clindamycin Phosphate	Clindamycin Phosphate	13	suppressed
Clonidine Hcl	Clonidine Hcl	13	suppressed
Dapagliflozin	Dapagliflozin Propanediol	13	suppressed
Fenofibrate	Fenofibrate	13	suppressed
Klor-Con 10	Potassium Chloride	13	suppressed
Lactulose	Lactulose	13	suppressed
Lidocaine	Lidocaine	13	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	13	suppressed
Telmisartan	Telmisartan	13	suppressed
Valsartan	Valsartan	13	suppressed
Zenpep	Lipase/Protease/Amylase	13	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	12	suppressed
Benazepril Hcl	Benazepril Hcl	12	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	12	suppressed
Carbidopa-Levodopa Er	Carbidopa/Levodopa	12	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	12	suppressed
Dutasteride	Dutasteride	12	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	12	suppressed
Pirfenidone	Pirfenidone	12	suppressed
Premarin	Estrogens, Conjugated	12	suppressed
Tresiba Flextouch U-200	Insulin Degludec	12	suppressed
Trihexyphenidyl Hcl	Trihexyphenidyl Hcl	12	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	11	suppressed
Breyna	Budesonide/Formoterol Fumarate	11	suppressed
Bupropion Hcl Sr	Bupropion Hcl	11	suppressed
Exelon	Rivastigmine	11	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	11	suppressed
Galantamine Hbr	Galantamine Hbr	11	suppressed
Indapamide	Indapamide	11	suppressed
Methimazole	Methimazole	11	suppressed
Nyamyc	Nystatin	11	suppressed
Roflumilast	Roflumilast	11	suppressed
Solu-Medrol	Methylprednisolone Sod Succ/Pf	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$497.31 · 5 records	Impulse Dynamics (USA) Inc.	OFEV, Optimizer	1	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error